NCT04697628 2026-02-24
innovaTV 301
Seagen Inc.
Phase 3 Completed
Clinical Trials
210 trialsNCT04648033 2026-01-29
ARCADIAN
University of Oxford
Phase 1 Completed
NCT02998528 2026-01-06
CheckMate 816
Bristol-Myers Squibb
Phase 3 Completed
NCT02514681 2025-09-10
PRECIOUS
Japan Breast Cancer Research Group
Phase 3 Completed
NCT03482362 2025-08-03
EORTC1616
The Netherlands Cancer Institute
Phase 2 Completed
NCT00354393 2025-07-15
Combination Chemotherapy With or Without Surgery & Chemoradiotherapy in Patients With Malignant Pleural Mesothelioma
The Cleveland Clinic
Phase 2 Completed
NCT00540982 2025-07-02
Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction
City of Hope Medical Center
Phase 1/2 Completed
NCT06533722 2025-06-10
Adaptive Therapy for Post-Second-Line Advanced Breast Cancer
Sun Yat-sen University
Phase 2 Completed
NCT03242616 2025-04-17
PemVin vs Vin in Previously Treated Metastatic Breast Cancer
Seoul National University Hospital
Phase 2 Completed
NCT03442673 2025-03-28
MOCCCA
Insel Gruppe AG, University Hospital Bern
Phase 2 Completed
NCT02489903 2025-03-17
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
Phase 2 Completed
NCT00324805 2025-03-03
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT03443128 2025-02-13
Vinorelbine for Recurrent ALCL-2017
Children's Cancer Group, China
Phase 2 Completed
NCT02892123 2024-11-27
Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers
Jazz Pharmaceuticals
Phase 1 Completed
NCT00309998 2024-10-29
Vinorelbine and Bevacizumab in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
University of Rochester
Phase 2 Completed
NCT03191786 2024-10-23
IPSOS
Hoffmann-La Roche
Phase 3 Completed
NCT03901339 2024-10-21
TROPiCS-02
Gilead Sciences
Phase 3 Completed
NCT03839823 2024-10-09
RIGHT Choice
Novartis
Phase 2 Completed
NCT03355157 2024-10-01
PADMA
GBG Forschungs GmbH
Phase 4 Completed
NCT02352948 2024-07-26
ARCTIC
AstraZeneca
Phase 3 Completed
NCT03887130 2024-04-30
Study of Oral Vinorelbine Plus Capecitabine Versus Taxane-gemcitabine Combinations as 1st Line Chemotherapy in Metastatic Breast Cancer
Pierre Fabre Medicament
Phase 2 Completed
NCT03321981 2024-03-07
MCLA-128 With Trastuzumab/Chemotherapy in HER2+ and With Endocrine Therapy in ER+ and Low HER2 Breast Cancer.
Merus B.V.
Phase 2 Completed
NCT02954055 2024-02-26
METEORA-II
ETOP IBCSG Partners Foundation
Phase 2 Completed
NCT02709720 2024-01-11
NORA
Spanish Lung Cancer Group
Phase 2 Completed
NCT03262935 2023-10-19
TULIP
Byondis B.V.
Phase 3 Completed
NCT00574496 2023-09-28
Combination Chemotherapy Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or High-Risk Primary Refractory Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00602797 2023-09-26
Vinorelbine Tartrate and Paclitaxel in Treating Older Patients With Advanced Non-Small Cell Lung Cancer
University of Nebraska
Phase 2 Completed
NCT00005847 2023-06-22
Chemotherapy With or Without Biological Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT03345810 2023-06-15
DURATION
AIO-Studien-gGmbH
Phase 2 Completed
NCT00128310 2023-05-31
Vinorelbine Versus Gemcitabine Plus Vinorelbine in Metastatic Breast Cancer Patients
Spanish Breast Cancer Research Group
Phase 3 Completed
NCT02915744 2023-04-14
ATTAIN
Nektar Therapeutics
Phase 3 Completed
NCT02555007 2022-11-17
NVB Metro
Assistance Publique Hopitaux De Marseille
Phase 1 Completed
NCT03397953 2022-07-26
Vinorelbine for Recurrent ACLC
Children's Cancer Group, China
Phase 2 Completed
NCT02574455 2022-06-15
ASCENT
Gilead Sciences
Phase 3 Completed
NCT00887783 2022-05-17
NARLAL
Odense University Hospital
Phase 2 Completed
NCT03801304 2022-05-12
VinMetAtezo
University Hospital, Brest
Phase 2 Completed
NCT01026220 2022-04-28
Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma
Children's Oncology Group
Phase 3 Completed
NCT03254654 2022-04-20
Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer
Fudan University
Phase 2 Completed
NCT04903652 2022-04-07
Pyrotinib Maleate Combined With Vinorelbine in the Treatment of HER2-positive Advanced Breast Cancer
Tianjin Medical University Cancer Institute and Hospital
Phase 2 Completed
NCT02555657 2021-12-10
KEYNOTE-119
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02139904 2021-10-12
VIM
Wales Cancer Trials Unit
Phase 2 Completed
NCT01802970 2021-10-08
Safety and Blood Immune Cell Study of Anakinra Plus Physician's Chemotherapy Choice in Metastatic Breast Cancer Patients
Baylor Research Institute
Phase 1 Completed
NCT00302003 2021-03-30
Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma
Children's Oncology Group
Phase 3 Completed
NCT01835236 2021-03-30
Trastuzumab & Pertuzumab Followed by T-DM1 in MBC
Swiss Cancer Institute
Phase 2 Completed
NCT00381940 2021-03-24
Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy
National Cancer Institute (NCI)
Phase 2 Completed
NCT02610140 2020-11-04
Phase II Anetumab Ravtansine as 2nd Line Treatment for Malignant Pleural Mesothelioma (MPM)
Bayer
Phase 2 Completed
NCT00006682 2020-08-14
Vinorelbine and Docetaxel in Treating Women With Metastatic Breast Cancer
Medstar Health Research Institute
Phase 2 Completed
NCT00003963 2020-08-03
Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With B-cell Non-Hodgkin's Lymphoma That Has Relapsed Following Peripheral Stem Cell Transplantation
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT01950182 2020-07-15
SYSUCC-002
Sun Yat-sen University
Phase 3 Completed
NCT02362958 2020-07-15
A Multi-Center Study of Lapatinib in Patients With Trastuzumab-refractory Metastatic Breast Cancer
Sun Yat-sen University
Phase 2 Completed